Immune-Mediated Polyarthritis (IMPA) in Dogs and Cats

TL;DR. Immune-mediated polyarthritis is a common, treatable inflammatory condition where a pet's immune system mistakenly targets multiple joints, causing fever, pain, and a stiff, "walking on eggshells" gait.

A stiff, hunched posture and reluctance to move are common early signs of joint pain in pets with IMPA.

What is it?

Immune-mediated polyarthritis (IMPA) is a disease where a pet’s own immune system mistakenly targets the joints, causing widespread inflammation. In a healthy animal, the immune system produces antibodies to target and destroy foreign invaders like bacteria or viruses. In pets with IMPA, the immune system produces antibody-antigen clusters called "immune complexes" that circulate in the bloodstream. These complexes eventually settle inside the synovial membrane, which is the delicate, fluid-producing lining of the joints.

Once these immune complexes lodge in the joint lining, they trigger a cascade of inflammation. This is known as nonseptic inflammation, meaning the joint is highly inflamed but does not contain an active bacterial infection. Because the immune complexes travel through the bloodstream, they usually settle in multiple joints simultaneously. This is why the condition is called "polyarthritis" (inflammation of multiple joints) rather than arthritis in a single joint.

Veterinarians classify polyarthritis into two main categories: erosive and nonerosive. Erosive polyarthritis, such as rheumatoid arthritis, is rare and physically destroys the cartilage and bone within the joint. IMPA is typically nonerosive, meaning that while the joint is painful, swollen, and inflamed, the underlying bone structure remains intact. While IMPA is most frequently diagnosed in dogs, it can also affect cats.

Causes & risk factors

IMPA can be primary (idiopathic) or secondary (reactive). Idiopathic IMPA means the disease occurs on its own with no identifiable trigger. This is the most common form of the disease. Secondary or reactive IMPA occurs when an underlying trigger elsewhere in the body causes the immune system to overreact and produce the immune complexes that settle in the joints.

According to a leading veterinary internal medicine reference, the classification of noninfectious, nonerosive polyarthritis includes:

• Idiopathic IMPA: No underlying cause can be identified.
• Systemic Lupus Erythematosus (SLE): A broader autoimmune disease where the body attacks multiple organs, including the joints.
• Reactive Polyarthritis: Triggered by an underlying inflammatory or infectious process elsewhere in the body. This can include gastrointestinal disease, chronic infections, cancers, drug reactions, or recent vaccinations.
• Breed-Associated Syndromes: Certain dog breeds have genetic predispositions to developing unique forms of polyarthritis.

Several dog breeds are suspected to have a genetic predisposition to IMPA. These include the Weimaraner, Newfoundland, Chinese Shar-Pei, Boxer, Bernese Mountain Dog, German Shorthaired Pointer, Beagle, and [Akita Inu](/p/breeds/akitainu_dog).

Signs to watch for

The signs of IMPA can appear suddenly or develop gradually over several weeks. Because the inflammation is systemic, pets often show signs of full-body illness alongside joint-specific symptoms.

Key symptoms to watch for include:

• Fever (Cardinal): A high body temperature is the most consistent sign of IMPA and often does not respond to standard antibiotics.
• Lameness (Common): Your pet may limp on one or more legs, and the lameness may seem to shift from one leg to another over time.
• Walking on Eggshells Gait (Common): Because multiple joints are painful at the same time, affected pets often walk with a very stiff, cautious, gingerly gait, as if walking on hot coals or eggshells.
• Joint Pain and Stiffness (Common): Your pet may struggle to stand up, climb stairs, or jump onto furniture. They may cry out when touched or when their legs are moved.
• Joint Swelling (Common): You may notice visible swelling or warmth in the larger joints, such as the wrists (carpi) or ankles (tarsi).
• Lethargy and Anorexia (Common): Affected pets are often extremely tired, reluctant to move, and may refuse to eat.
• Cervical Pain (Occasional): Some pets experience severe neck pain because the small joints between the neck vertebrae can also become inflamed.

Visible swelling and warmth in the lower leg joints, such as the wrists, can indicate active joint inflammation.

How vets diagnose it

Diagnosing IMPA requires a systematic approach to confirm joint inflammation and rule out other potential causes, such as direct joint infections or tick-borne diseases. Your vet will perform a thorough physical and orthopedic examination, followed by specific diagnostic tests.

• Synovial Fluid Analysis (Gold Standard): To confirm a diagnosis of IMPA, your vet must perform a joint tap. Under sedation or anesthesia, a small needle is inserted into several joints (usually the wrists, ankles, and knees) to collect a sample of the joint fluid (synovial fluid). In a healthy joint, this fluid is clear, viscous, and contains very few cells. In a pet with IMPA, the fluid is thin, watery, and contains a very high number of white blood cells, specifically neutrophils.

As noted in a leading veterinary internal medicine reference:

"Synovial fluid analysis reveals an increase in both white blood cell (WBC) count and the percentage of neutrophils in affected joints, but synovial fluid culture is negative. Even if the underlying inflammatory disease is infectious, the polyarthritis in these patients is caused by synovial deposition of circulating immune complexes, not by infection of the joints."

• Radiography (X-rays): Your vet will take X-rays of the affected joints to confirm that the disease is nonerosive. In pets with IMPA, the X-rays typically show joint swelling (fluid buildup) but no destruction of the surrounding bone.
• Complete Blood Count (CBC): This blood test helps evaluate the severity of systemic inflammation and rules out other blood-related abnormalities.
• Antinuclear Antibody (ANA) Titer: If your vet suspects your pet has systemic lupus erythematosus (SLE) due to the involvement of multiple organ systems, they may run an ANA titer to look for specific autoantibodies.

X-rays help veterinarians confirm that the joint inflammation is nonerosive, meaning the underlying bone remains undamaged.

Treatment options

Treatment for IMPA focuses on suppressing the overactive immune response to stop the inflammation and relieve pain. If an underlying cause for reactive polyarthritis is identified, that primary condition must be treated simultaneously.

First-Line Therapies

• Glucocorticoids (Corticosteroids): High-dose steroid therapy (such as prednisone or prednisolone) is the primary treatment for IMPA. Steroids rapidly suppress the immune system and reduce joint inflammation. Once your pet's symptoms resolve and their joint fluid returns to normal, the steroid dose is very slowly tapered over several months to the lowest effective dose, or discontinued entirely.
• Doxycycline (Tetracycline Antibiotic): Vets often prescribe doxycycline at the start of treatment. This is done to treat potential tick-borne infections (like Lyme disease or Anaplasma) that can trigger reactive joint inflammation, and because doxycycline has mild anti-inflammatory properties.

Second-Line Therapies

If your pet does not respond to steroids, experiences severe side effects from them, or flares up during the tapering process, your vet may add a second immunosuppressive or immunomodulating agent. These medications include:

• Cyclosporine
• Leflunomide
• Mycophenolate Mofetil
• Azathioprine (Note: Azathioprine must never be used in cats due to life-threatening bone marrow toxicity)
• Chlorambucil
• Cyclophosphamide
• Methotrexate

According to a leading veterinary internal medicine reference:

"Additional immunosuppressive agents are rarely necessary, because idiopathic nonerosive IMPA is easy to control in most patients. If the polyarthritis is refractory to treatment, the patient should be reevaluated for infectious disease, reactive polyarthritis, and erosive disease prior to considering alternative immunosuppressive agents."

Prognosis

The prognosis for pets with idiopathic nonerosive IMPA is generally good. Most dogs and cats respond well to initial steroid therapy, and many can eventually be tapered off medications entirely. However, some pets require lifelong, low-dose medication to keep the disease in remission.

The prognosis becomes more guarded to poor if the polyarthritis is associated with Systemic Lupus Erythematosus (SLE) or certain severe, breed-specific syndromes. If your pet experiences frequent relapses during medication tapering, long-term management can become more challenging and may require combination drug therapy.

Prevention

Because idiopathic IMPA is an autoimmune disease, there is no known way to prevent it. For reactive IMPA, prompt treatment of systemic infections, avoiding medications known to trigger adverse drug reactions in your pet, and discussing tailored vaccination protocols with your vet can help minimize the risk of a flare-up.

When to call your vet

If your pet shows any signs of joint pain, stiffness, or unexplained lethargy, schedule an appointment with your veterinarian.

Seek immediate emergency veterinary care if your pet:

• Develops a very high fever
• Refuses to stand or walk entirely
• Shows signs of extreme neck pain (screaming when moving their head, holding their head low to the ground)
• Becomes completely unresponsive or severely lethargic
• Develops difficulty breathing or pale gums while taking immunosuppressive medications

For specific breeds

If you own a Weimaraner, Newfoundland, Chinese Shar-Pei, Boxer, Bernese Mountain Dog, German Shorthaired Pointer, Beagle, or Akita Inu, be extra vigilant for signs of stiffness or fever. Akita Inus, in particular, can suffer from a severe, breed-specific immune-mediated syndrome that involves both joint inflammation and meningitis (inflammation of the brain and spinal cord linings). This specific syndrome is often highly resistant to treatment and carries a more guarded prognosis.

Sources

• Internal Medicine, 5th Edition, pages 1152, 1153, 1154, 1465, 1466.